Previous 10 | Next 10 |
The following slide deck was published by Cassava Sciences, Inc. in conjunction with this event. For further details see: Cassava Sciences (SAVA) Investor Presentation - Slideshow
Betting on turnarounds in companies that others are too scared to touch can be a successful strategy for some investors. That's because the market often overreacts to bad news. Farsighted investors who recognize the enduring potential of a business -- even during its most vulnerable hours -...
March 30 saw the retraction of five papers where Dr Hoau-Yan Wang, a key scientific collaborator of SAVA, is an author. Dr Lindsay Burns, Senior VP, neurosciences, at SAVA is also an author on two of the recently retracted papers. The City University of New York (CUNY) might soon ...
Palm Beach, FL – March 31, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia among the elderly, accounting for between 60% and 80...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cassava Sciences ( SAVA ) is risky but worthwhile after clarity emerges following scandal. The biotech company is well-funded and has blockbuster potential with its Alzheimer’s drug, Simufilam. B...
– CEO Remi Barbier to Discuss Q1 2022 Clinical and Corporate Updates – – Stakeholders Are Invited to Submit Questions via Email – – Fireside Chat Will Be Open to The Public via Webcast – AUSTIN, Texas, March 30, 2022 (GLOBE...
Aricept and blarcamesine limit further oxidative stress in Alzheimer's disease via agonism of Sigma-1 receptors. Simufilam may do the same. Aricept, blarcamesine, and simufilam either directly or indirectly increase ketone levels which catalyze the decomposition of the nitro-oxidant p...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips There is good news and bad news with the big sell-off of Cassava Sciences (NASDAQ: SAVA ). The good news is that much of its decline over the past month, which has taken SAVA stock from $50 down to around $34 per...
Because many receptors and factors lead to the onset and early progression of Alzheimer's disease, targeting any one of them only slightly slows down the progression of Alzheimer's in subgroups. Targeting intervening points between receptor overactivation and peroxynitrite formation, ...
Cassava Sciences may have removed an outlier in the drug group turning a negative result into a positive one, leading to a windfall for its CEO and chief scientific investigator. Cassava Sciences stated mechanisms of action do not explain its results. Simufilam may be a sigma-1 re...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...